tetano
Editor, Senior Moderator
Curr Cancer Drug Targets
. 2022 Feb 15.
doi: 10.2174/1568009622666220215143805. Online ahead of print.
The Interactions among Hypertension, Cancer, and COVID-19: Perspectives from Ca2+/cAMP Signalling
Leandro Bueno Bergantin[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The hypothesis that hypertension is clinically associated with an enhanced risk for developing cancer has been highlighted. However, the working principles involved in this link are still under intensive discussion. A correlation among inflammation, hypertension, and cancer could accurately describe the clinical link between these diseases. In addition, a dyshomeostasis of Ca[SUP]2+[/SUP] has been considered as a topic involved in both cancer and hypertension and inflammation. There is a strong link between Ca[SUP]2+[/SUP] signalling, e.g. enhanced Ca[SUP]2+[/SUP] signals, and inflammatory outcomes. cAMP also modulates pro- and anti-inflammatory outcomes: pharmaceuticals, which increase intracellular cAMP levels, can decrease the production of proinflammatory mediators and enhance the production of anti-inflammatory outcomes.
Objective: This article has discussed the participation of Ca[SUP]2+[/SUP]/cAMP signalling in the clinical association among inflammation, hypertension, and an enhanced risk for the development of cancer. In addition, considering coronavirus disease 2019 (COVID-19) is a rapidly evolving field, this article also reviews recent reports about the role of Ca[SUP]2+[/SUP] channel blockers for restoring Ca[SUP]2+[/SUP] signalling disruption due to COVID-19, including the relationship among COVID-19, cancer, and hypertension.
Conclusion: Understanding the association among these diseases could expand current pharmacotherapy, including that involving Ca[SUP]2+[/SUP] channel blockers and pharmaceuticals which rise cAMP levels.
Keywords: COVID-19; Ca2+ channel blockers; Ca2+/cAMP signalling; Cancer; hypertension; inflammation.
. 2022 Feb 15.
doi: 10.2174/1568009622666220215143805. Online ahead of print.
The Interactions among Hypertension, Cancer, and COVID-19: Perspectives from Ca2+/cAMP Signalling
Leandro Bueno Bergantin[SUP] 1 [/SUP]
Affiliations
- PMID: 35168520
- DOI: 10.2174/1568009622666220215143805
Abstract
Background: The hypothesis that hypertension is clinically associated with an enhanced risk for developing cancer has been highlighted. However, the working principles involved in this link are still under intensive discussion. A correlation among inflammation, hypertension, and cancer could accurately describe the clinical link between these diseases. In addition, a dyshomeostasis of Ca[SUP]2+[/SUP] has been considered as a topic involved in both cancer and hypertension and inflammation. There is a strong link between Ca[SUP]2+[/SUP] signalling, e.g. enhanced Ca[SUP]2+[/SUP] signals, and inflammatory outcomes. cAMP also modulates pro- and anti-inflammatory outcomes: pharmaceuticals, which increase intracellular cAMP levels, can decrease the production of proinflammatory mediators and enhance the production of anti-inflammatory outcomes.
Objective: This article has discussed the participation of Ca[SUP]2+[/SUP]/cAMP signalling in the clinical association among inflammation, hypertension, and an enhanced risk for the development of cancer. In addition, considering coronavirus disease 2019 (COVID-19) is a rapidly evolving field, this article also reviews recent reports about the role of Ca[SUP]2+[/SUP] channel blockers for restoring Ca[SUP]2+[/SUP] signalling disruption due to COVID-19, including the relationship among COVID-19, cancer, and hypertension.
Conclusion: Understanding the association among these diseases could expand current pharmacotherapy, including that involving Ca[SUP]2+[/SUP] channel blockers and pharmaceuticals which rise cAMP levels.
Keywords: COVID-19; Ca2+ channel blockers; Ca2+/cAMP signalling; Cancer; hypertension; inflammation.